Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
PZ HTL SA
GLOBETECH PUBLISHING LLC

New Drug Combinations Block Kidney Cancer in Culture and Mouse Models

By BiotechDaily International staff writers
Posted on 20 May 2013
Image: Senior author Dr. John Copland (Photo courtesy of the Mayo Clinic).
Image: Senior author Dr. John Copland (Photo courtesy of the Mayo Clinic).
Drugs that block the activity of the enzyme Stearoyl-CoA desaturase-1 (SCD1) repress the growth of kidney cancer cells in culture and in mouse models of the disease.

SCD1, which is overexpressed in most kidney cancer samples, is a key enzyme in fatty acid metabolism responsible for forming a double bond in Stearoyl-CoA. This is the way that the monounsaturated fatty acid oleic acid is produced from the saturated fatty acid stearic acid. The ratio of stearic acid to oleic acid has been implicated in the regulation of cell growth and differentiation through effects on cell membrane fluidity and signal transduction.

Investigators at the Mayo Clinic (Jacksonville, FL, USA) worked with a drug that had been designed to block the activity of SCD1 in clear cell renal cell carcinoma (ccRCC), which accounts for almost 85% of kidney cancer cases in the United States.

The investigators examined patient normal and ccRCC tissue samples and cell lines for SCD1 expression. Genetic knockdown models and targeted inhibition of SCD1 through the use of the drug A939572 were analyzed for growth, apoptosis, and alterations in gene expression using gene array analysis. Models of combined therapy using A939572 and the tyrosine kinase inhibitors (TKI) sunitinib and pazopanib, and the mTOR inhibitor temsirolimus were evaluated.

Results published in the May 1, 2013, issue of the journal Clinical Cancer Research revealed increased SCD1 expression in all stages of ccRCC. Both genetic knockdown and pharmacologic inhibition of SCD1 decreased tumor cell proliferation and induced apoptosis in vitro and in vivo. Upon gene array, quantitative real-time PCR, and protein analysis of A939572-treated or genetic SCD1 knockdown samples, induction of endoplasmic reticulum stress response signaling was observed, which suggested a mechanistic mechanism for SCD1 activity in ccRCC. Furthermore, application of A939572 (25% inhibition when applied alone) combined with temsirolimus inhibited tumor growth by 60%–70% in vitro and in vivo.

“There is a clear need for new therapies for this common cancer. With very few exceptions, patients inevitably become resistant to all available treatments,” said senior author Dr. John Copland, professor of cancer biology at the Mayo Clinic.

“We found it [A939572] to be incredibly specific to cancer cells in laboratory mice treated with the agent,” said Dr. Copland. “But these are early days in the testing of this agent for cancer. The synergy between the drugs [A939572 and temsirolimus] was very striking, suggestive of significant clinical benefit in patients.”

Related Links:
Mayo Clinic



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: This novel, flexible film that can react to light is a promising step toward an artificial retina (Photo courtesy of the American Chemical Society).

Novel Nanofilm May Be Artificial Retina Precursor

Researchers have used advanced nanotechnology techniques to develop a light-sensitive film that has potential for future artificial retina applications. Investigators at the Hebrew University of Jerusalem... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Business

view channel

R&D Partnership Initiated to Reduce Development Time for New Drugs

nanoPET Pharma, GmbH (Berlin, Germany) signed an open-ended framework contract with the international pharmaceutical company Boehringer Ingelheim (Ridgefield, CT, USA). By developing customized contrast agents for research in both basic and preclinical studies, nanoPET Pharma will contribute to the enhancement of Boehringer... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.